Islatravir/Doravirine As Effective As Other ART Regimens In Maintaining Viral Suppression Among Patients With HIV-1, Trials Show

MedPage Today (3/18, Haelle) reports , “Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF; Biktarvy) or continuing a previous antiretroviral therapy (ART) in maintaining viral suppression among people with HIV-1, two phase III trials showed.” Researchers said, “There is an unmet need for novel antiretroviral regimens that are highly potent and maintain viral control with minimal long-term toxicity and fewer drug interactions. This is the first phase III trial to demonstrate that a two-drug regimen without an integrase inhibitor is noninferior to BIC/FTC/TAF.” The research was presented at the Conference on Retroviruses and Opportunistic Infections (CROI).